Last reviewed · How we verify
Thromboembolic disorder
Approved treatments
- Proendotel
Cloricromen works by inhibiting platelet aggregation, which is the process by which platelets clump together to form blood clots. - Coumadin · Generic (originally Wisconsin Alumni Research Foundation)
Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis. - Dicuman · AbbVie
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Thromboembolic disorder patent landscape — cliff calendar, originator estates, attackable patents
- Thromboembolic disorder treatment landscape brief
- Thromboembolic disorder treatment updates RSS
Frequently asked questions about Thromboembolic disorder
What drugs treat Thromboembolic disorder?
Tracked treatments include Proendotel, Coumadin, Dicuman.
What is the treatment for Thromboembolic disorder?
Standard treatment for Thromboembolic disorder includes Proendotel, Coumadin, Dicuman. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Thromboembolic disorder patent cliff · Thromboembolic disorder CI report
- Treatment: Proendotel
- Treatment: Coumadin · Generic (originally Wisconsin Alumni Research Foundation)
- Treatment: Dicuman · AbbVie
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing